There is hope that the ongoing Phase II trial of the BRAF/MEK inhibitors vemurafenib and cobimetinib for the treatment of PCP (NCT03224767) will provide stronger clinical evidence for the efficacy of this combination in BRAF-V600E-positive PCP patients. The gene discussed is BRAF; the disease is pneumocystosis.